BioSpace News Archive

As part of its ongoing commitment to support clinical oncology research, Thermo Fisher Scientific is calling for new proposals for its Oncomine Clinical Research Grant.

Ra Medical Systems, Inc. (NYSE American: RMED), announces the filing of a 510(k) application with the U.S. Food and Drug Administration (FDA) for the company’s next-generation DABRA catheter with a braided overjacket and a six-month shelf life as a device for crossing chronic total occlusions in patients with symptomatic infrainguinal lower extremity vascular disease and with an intended use for ablating a channel in occlusive peripheral vascular disease.

Veracyte, Inc., a global diagnostics company, announced that it has appointed Annie McGuire as senior vice president and general counsel, effective immediately.

Akari Therapeutics, Plc (Nasdaq: AKTX), today announced new data showing that clinical outcomes in U.S. Army trauma patients correlate with complement activation, and that nomacopan significantly improves survival from 30% to 80% in a clinically relevant preclinical model of traumatic hemorrhage.

Serotiny, a leader in high-throughput therapeutic Multi-Domain Protein (tMDP) engineering, and Tessera Therapeutics, a biotechnology company pioneering a new approach in genetic medicines known as Gene Writing technology, today announced a collaboration to engineer programmable Gene Writer proteins.

“We have continued to make important progress in our Phase 1 clinical trial with NVG-291 in the fourth quarter of 2021 and early 2022,” stated Paul Brennan, NervGen’s President & CEO.

NeuroLogica Corp., the U.S. healthcare subsidiary of Samsung, announced that the company’s Digital Radiography and Ultrasound business will operate under a new brand called Boston Imaging™.

Boston Scientific Corporation (NYSE: BSX) today announced positive results from a new analysis assessing real-world outcomes with the WATCHMAN FLX™ Left Atrial Appendage Closure (LAAC) Device. Presented during a late-breaking trial session at the Cardiovascular Research Technologies (CRT) 2022 meeting.

Herophilus, a leading biotechnology company developing neurotherapeutics to cure complex brain diseases, today announced the publication of research that describes a new statistical method to identify and analyze the effects of potentially confounding variables on machine learning models for complex biological datasets.

Actym Therapeutics, a biotechnology company focused on the discovery and development of novel therapies intended to transform the treatment of cancer, and Wacker Biotech announced today that they have signed a contract for the manufacturing of Actym’s lead clinical candidate, ACTM-838, for the treatment of solid tumors.